Treatment of Agitation by drug Aerosol Inhalation

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$196,998.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH068926-01A1
Award Id:
71726
Agency Tracking Number:
MH068926
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ALEXZA MOLECULAR DELIVERY CORPORATION, 1001 E MEADOW CIR, PALO ALTO, CA, 94303
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PATRIK MUNZAR
(650) 687-3922
PMUNZAR@ALEXZA.COM
Business Contact:
JOSHUA RABINOWITZ
(650) 687-3902
JRABINOWITZ@ALEXZA.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Acute agitation is a serious and common complication of a variety of major psychiatric disorders, including dementia, schizophrenia and mania. In addition, it is one of the most detrimental factors in the continued stigmatization of mental illness. The current standard in its management is either oral or intramuscular administration of antipsychotics and/or benzodiazepines. The major disadvantage of these management techniques is relatively slow onset of drug action. There is thus a clear medical need for rapid, non-invasive techniques to treat acute agitation. The goal of this proposal is to develop a device that rapidly delivers agitation treatment via deep-lung inhalation. Our product is targeting a subgroup of agitated patients who are willing to cooperate with caregivers (according to several surveys, more that half of agitated patients want to be medicated and take medications willingly during emergency treatment). Our company has developed an aerosol generation technology that enables rapid and reproducible delivery of many FDA-approved drugs to the systemic circulation and brain through inhalation using a compact inhaler. In this Phase I grant, we will prove the feasibility of using this technology to deliver two anti-agitation drugs, one antipsychotic and one benzodiazepine. In a subsequent Phase II grant, we will optimize the inhaler for use by agitated patients, and will complete all inhalation toxicology studies necessary for filing an Investigational New Drug application (IND) with the FDA. Clinical development of the new treatment of acute agitation would then be funded by outside investors or through a partnership with a major pharmaceutical company. Eventual approval of our inhaled product will markedly expand treatment options in behavioral emergencies and will likely substantially improve quality of life of patients who experience acute agitation.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government